CD19.CAR Allogeneic NKT

CD19-targeted allogeneic natural killer T cell therapy

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD19.CAR Allogeneic NKT, covering 2025-07-01 to 2025-07-01. Get the full timeline:

Most recent: Clinical Trial Update: CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) [Phase 1]